Joyce Cramer

List of Articles by Year
in descending order

Source: //exaly.com/author-pdf/7208334/publications.pdf

Version: 2025-02-01

156 peer-reviewed articles	16,246 peer-reviewed citations	23760 58 peer-reviewed h-index	449993 4.09 score
172 documents	18972 doc citations	21781 64 h-index	27409 citing authors

#	Article	IF	Citations
1	Minimum clinically important difference (MCID) of the personal impact of epilepsy scale (PIES). Epilepsy and Behavior, 2022, 130, 108691.	1.4	2
2	Quality-of-life results in adults with epilepsy using diazepam nasal spray for seizure clusters from a long-term, open-label safety study. Epilepsy and Behavior, 2022, 134, 108811.	1.4	17
3	Risk of hospitalization among patients with epilepsy using long versus short half-life adjunctive antiepileptic drugs. Epilepsy and Behavior, 2020, 102, 106634.	1.4	5
4	Living safely with epilepsy: a key learning review. Epileptic Disorders, 2020, 22, 364-380.	1.2	9
5	Associations between seizure severity change and patient characteristics, changes in seizure frequency, and health-related quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate: Post hoc analyses of clinical trial results. Epilepsy and Behavior, 2020, 112, 107312.	1.4	9
6	Identification of seizure clusters using free text notes in an electronic seizure diary. Epilepsy and Behavior, 2020, 113, 107498.	1.4	5
7	Assessing the personal impact of epilepsy in a population-based cohort of Veterans. Epilepsy and Behavior, 2020, 106, 107047.	1.4	13
8	Computational analysis of Seizure Clusters in electronic diary free text notes (1226). Neurology, 2020, 94, .	0.7	0
9	Health-related quality of life in patients treated with eslicarbazepine acetate monotherapy: Pooled analysis from two registered clinical trials. Epilepsy and Behavior, 2019, 92, 31-35.	1.4	5
10	Risk of Hospitalization in Patients With Uncontrolled Epilepsy Treated with a Long Versus Short Half-Life Adjunctive Antiepileptic Medication (P3.5-002). Neurology, 2019, 92, .	0.7	0
11	Adherence with Extended-Release Oxcarbazepine (Oxtellar XR®) vs. Immediate-Release Oxcarbazepine: Analysis of Pooled Data from Four National Pharmacy Claims Databases (P6.293). Neurology, 2018, 90, .	0.7	1
12	Predictors of Clinically Meaningful Improvements in Health-Related Quality of Life Among Adults With Partial-Onset Epilepsy: A Pooled Analysis From Two Eslicarbazepine Acetate Monotherapy Trials (P6.283). Neurology, 2018, 90, .	0.7	0
13	Impact of seizure frequency reduction on health-related quality of life among clinical trial subjects with refractory partial-onset seizures: A pooled analysis of phase III clinical trials of eslicarbazepine acetate. Epilepsy and Behavior, 2017, 68, 203-207.	1.4	16
14	Treatment issues for children with epilepsy transitioning to adult care. Epilepsy and Behavior, 2017, 69, 153-160.	1.4	42
15	Antiepileptic drug class-related healthcare costs among pediatric patients initiating monotherapy treatment for partial-onset seizures (P3.228). Neurology, 2017, 88, .	0.7	0
16	Relationship between Seizure Frequency Reduction and Health-Related Quality of Life in Conversion-to-Monotherapy and Adjunctive Therapy Trials of Eslicarbazepine Acetate (P3.229). Neurology, 2017, 88, .	0.7	0
17	Eslicarbazepine Acetate Associated with Reduced Seizure Severity in Addition to Reduced Seizure Frequency (P2.031). Neurology, 2016, 86, .	0.7	0
18	Patients Treated with Eslicarbazepine Acetate Monotherapy Show Quality of Life Improvement (P2.028). Neurology, 2016, 86, .	0.7	0

#	Article	IF	Citations
19	Severity and burden of partial-onset seizures in a phase III trial of eslicarbazepine acetate. Epilepsy and Behavior, 2015, 53, 149-153.	1.4	8
20	Health-care costs and utilization related to long- or short-acting antiepileptic monotherapy use. Epilepsy and Behavior, 2015, 44, 40-46.	1.4	9
21	Use of an online epilepsy diary to characterize repetitive seizures. Epilepsy and Behavior, 2015, 47, 66-71.	1.4	84
22	The Personal Impact of Epilepsy Scale (PIES). Epilepsy and Behavior, 2015, 42, 140-146.	1.4	55
23	Is a separate monotherapy indication warranted for antiepileptic drugs?. Lancet Neurology, The, 2015, 14, 1229-1240.	13.7	42
24	Elucidating the transdiagnostic dimensional structure of trauma-related psychopathology: Findings from VA cooperative study 504 – risperidone treatment for military service related chronic post traumatic stress disorder. Journal of Affective Disorders, 2015, 172, 331-336.	3.1	12
25	A Comparison of Instruments to Measure Depressive Symptoms among Patients with Refractory Partial-Onset Seizures (P3.192). Neurology, 2015, 84, .	0.7	0
26	Baseline Depressive Symptoms as Predictive of Seizure Frequency Reduction among Epilepsy Patients with Partial-Onset Seizures: A Pooled Analysis of Phase III Clinical Trials of Adjunctive Treatment with Eslicarbazepine Acetate (P3.193). Neurology, 2015, 84, .	0.7	0
27	Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model. Current Medical Research and Opinion, 2014, 30, 2329-2341.	1.4	49
28	Determining minimally important change thresholds for the Seizure Severity Questionnaire (SSQ). Epilepsy and Behavior, 2014, 31, 286-290.	1.4	20
29	Healthcare utilization and costs in adults with stable and uncontrolled epilepsy. Epilepsy and Behavior, 2014, 31, 356-362.	1.4	159
30	Sensitivity testing of the Seizure Severity Questionnaire (SSQ). Epilepsy and Behavior, 2014, 31, 281-285.	1.4	16
31	Happy Anniversary, Epilepsy & Behavior. Epilepsy and Behavior, 2014, 40, 66.	1.4	0
32	Healthcare utilization and costs in children with stable and uncontrolled epilepsy. Epilepsy and Behavior, 2014, 32, 135-141.	1.4	84
33	Impact of Seizure Frequency Reduction on Health-Related Quality of Life Among Clinical Trial Subjects with Refractory Partial-Onset Seizures: A Pooled Analysis of Phase III Clinical Trials of Eslicarbazepine Acetate (P6.180). Neurology, 2014, 82, .	0.7	1
34	Utilisation of Free Valproic Acid Determinations. Clinical Pharmacokinetics, 2012, 9, 94-95.	2.1	0
35	Microelectronic Systems for Monitoring and Enhancing Patient Compliance With Medication Regimens. Drugs, 2012, 49, 321-327.	8.5	68
36	Enhancing Patient Compliance in the Elderly. Drugs and Aging, 2012, 12, 7-15.	2.3	63

#	Article	IF	Citations
37	Tolerability of antiepileptic drugs: Can we determine differences?. Epilepsy and Behavior, 2012, 23, 187-192.	1.4	11
38	Defining minimally important change in QOLIE-31 scores: Estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures. Epilepsy and Behavior, 2012, 23, 230-234.	1.4	90
39	Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service–Related PTSD. JAMA - Journal of the American Medical Association, 2011, 306, 493.	14.4	210
40	The evolution of antiepileptic drug development and regulation. Epileptic Disorders, 2010, 12, 3-15.	1.2	66
41	Abstract #8: Trial Methodology of a Randomized, Double-blind, Parallel-Group Study Evaluating the Clinical Effectiveness of Carisbamate, Topiramate, and Levetiracetam As Adjunctive Treatment of Partial Onset Seizures in Adults. Neurotherapeutics, 2010, 7, 330-331.	3.9	0
42	Cognition across the lifespan: Antiepileptic drugs, epilepsy, or both?. Epilepsy and Behavior, 2010, 17, 1-5.	1.4	120
43	Methodological approach to the definition of “non-adherence”. Epilepsy and Behavior, 2009, 15, 264.	1.4	2
44	Linguistic Validation of the Japanese Version of the Quality of Life in Epilepsy Inventory (QOLIE-31-P). Journal of the Japan Epilepsy Society, 2009, 27, 22-32.	0.1	16
45	Quantitative Assessment of Seizure Severity for Clinical Trials: A Review of Approaches to Seizure Components. Epilepsia, 2008, 42, 119-129.	3.0	89
46	Medication Compliance and Persistence: Terminology and Definitions. Value in Health, 2008, 11, 44-47.	1.0	1,976
47	Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Current Medical Research and Opinion, 2007, 23, 2193-2203.	1.4	42
48	Improved Adherence with Contingency Management. AIDS Patient Care and STDs, 2007, 21, 30-40.	2.1	186
49	Women with epilepsy: Hormonal issues from menarche through menopause. Epilepsy and Behavior, 2007, 11, 160-178.	1.4	38
50	The impact of seizures and adverse effects on global health ratings. Epilepsy and Behavior, 2007, 11, 179-184.	1.4	29
51	Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis. Current Medical Research and Opinion, 2007, 23, 2369-2377.	1.4	21
52	New Insights into the Efficacy of Naltrexone Based on Trajectory-Based Reanalyses of Two Negative Clinical Trials. Biological Psychiatry, 2007, 61, 1290-1295.	3.8	45
53	A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases. Value in Health, 2007, 10, 3-12.	1.0	578
54	Methods for Integrating Medication Compliance and Persistence in Pharmacoeconomic Evaluations. Value in Health, 2007, 10, 498-509.	1.0	87

#	Article	IF	Citations
55	Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology, 2007, 192, 253-260.	1.8	110
56	Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporosis International, 2007, 18, 711-719.	2.7	145
57	A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporosis International, 2007, 18, 1023-1031.	2.7	418
58	Reduced Fracture Rates Observed Only in Patients With Proper Persistence and Compliance With Bisphosphonate Therapies. Southern Medical Journal, 2007, 100, 1214-1218.	0.4	28
59	The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France. Clinical Therapeutics, 2006, 28, 1686-1694.	1.9	100
60	Response to Compliance With Hypertension Therapy: Why Standards Are Needed. Hypertension, 2006, 48, .	4.7	0
61	Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Current Medical Research and Opinion, 2005, 21, 1453-1460.	1.4	376
62	Differentiating anxiety and depression symptoms in patients with partial epilepsy. Epilepsy and Behavior, 2005, 6, 563-569.	1.4	64
63	Different aspects of adherence to antihypertensive treatments. Expert Review of Pharmacoeconomics and Outcomes Research, 2004, 4, 317-333.	1.0	5
64	Compliance with Inhaled Insulin Treatment Using the AERx®iDMS Insulin Diabetes Management System. Diabetes Technology and Therapeutics, 2004, 6, 800-807.	3.8	22
65	A Systematic Review of Adherence With Medications for Diabetes. Diabetes Care, 2004, 27, 1218-1224.	5.6	1,115
66	Quality of life improvement with conversion to lamotrigine monotherapy. Epilepsy and Behavior, 2004, 5, 224-230.	1.4	46
67	The impact of comorbid depression on health resource utilization in a community sample of people with epilepsy. Epilepsy and Behavior, 2004, 5, 337-342.	1.4	150
68	Improved mood states with lamotrigine in patients with epilepsy. Epilepsy and Behavior, 2004, 5, 702-707.	1.4	39
69	Development of a growth hormone injection questionnaire for adolescents. Journal of Adolescent Health, 2004, 34, 27-29.	1.6	8
70	Electronic monitoring and counseling to improve medication adherence. Behaviour Research and Therapy, 2004, 42, 409-422.	2.2	122
71	Title is missing!. Journal of Behavioral Medicine, 2003, 26, 349-360.	1.3	52
72	Tolerability of levetiracetam in elderly patients with CNS disorders. Epilepsy Research, 2003, 56, 135-145.	1.3	58

#	Article	IF	Citations
73	Medication Compliance Feedback and Monitoring in a Clinical Trial: Predictors and Outcomes. Value in Health, 2003, 6, 566-573.	1.0	193
74	The Influence of Comorbid Depression on Seizure Severity. Epilepsia, 2003, 44, 1578-1584.	3.0	122
75	Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL. Schizophrenia Research, 2003, 63, 137-149.	1.6	155
76	The influence of comorbid depression on quality of life for people with epilepsy. Epilepsy and Behavior, 2003, 4, 515-521.	1.4	192
77	Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam. Epilepsy and Behavior, 2003, 4, 118-123.	1.4	135
78	A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy and Behavior, 2003, 4, 124-132.	1.4	168
79	Medicine partnerships. British Heart Journal, 2003, 89, 19ii-21.	5.4	6
80	The relationship between poor medication compliance and seizures. Epilepsy and Behavior, 2002, 3, 338-342.	1.4	213
81	Principles of Health-related Quality of Life: Assessment in Clinical Trials. Epilepsia, 2002, 43, 1084-1095.	3.0	63
82	Development of a new seizure severity questionnaire: initial reliability and validity testing. Epilepsy Research, 2002, 48, 187-197.	1.3	86
83	Psychometric Properties of the German Translation of the QOLIE-31. Epilepsy and Behavior, 2001, 2, 106-114.	1.4	88
84	Exploration of Changes in Health-Related Quality of Life after 3 Months of Vagus Nerve Stimulation. Epilepsy and Behavior, 2001, 2, 460-465.	1.4	66
85	A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics, 2001, 23, 1296-1310.	1.9	2,176
86	Naltrexone in the Treatment of Alcohol Dependence. New England Journal of Medicine, 2001, 345, 1734-1739.	26.4	614
87	Assessing the severity of seizures and epilepsy: which scales are valid?. Current Opinion in Neurology, 2001, 14, 225-229.	2.4	24
88	Refill Patterns of Atypical and Conventional Antipsychotic Medications at a National Retail Pharmacy Chain. Psychiatric Services, 2001, 52, 1248-1250.	1.3	29
89	Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Research, 2001, 47, 17-25.	1.3	96
90	Development and Validation of the Headache Needs Assessment (HANA) Survey. Headache, 2001, 41, 402-409.	1.7	40

#	Article	IF	Citations
91	The Short-Term Impact of Adjunctive Tiagabine on Health-Related Quality of Life. Epilepsia, 2001, 42, 70-75.	3.0	13
92	A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Research, 2001, 47, 77-90.	1.3	187
93	Detecting Improvement in Quality of Life and Symptomatology in Schizophrenia. Schizophrenia Bulletin, 2001, 27, 227-234.	2.9	53
94	Cue-dose training with monetary reinforcement. Journal of General Internal Medicine, 2000, 15, 841-847.	1.5	206
95	Comparison between the QOLIE-31 and derived QOLIE-10 in a clinical trial of levetiracetam. Epilepsy Research, 2000, 41, 29-38.	1.3	99
96	Effect of Levetiracetam on Epilepsy-Related Quality of Life. Epilepsia, 2000, 41, 868-874.	3.0	126
97	Quality of Life in Schizophrenia: A Comparison of Instruments. Schizophrenia Bulletin, 2000, 26, 659-666.	2.9	100
98	Brief Report : Adolescents' Attitudes Toward Epilepsy : Further Validation of the Child Attitude Toward Illness Scale (CATIS). Journal of Pediatric Psychology, 2000, 25, 339-345.	1.3	64
99	Development of the Quality of Life in Epilepsy Inventory for Adolescents: The QOLIE-AD-48. Epilepsia, 1999, 40, 1114-1121.	3.0	238
100	Risk Factors for Poor Health-Related Quality of Life in Adolescents with Epilepsy. Epilepsia, 1999, 40, 1715-1720.	3.0	192
101	New Antiepileptic Drugs: Comparison of Key Clinical Trials. Epilepsia, 1999, 40, 590-600.	3.0	191
102	Interrater Reliability Levels of Multiple Clinical Examiners in the Evaluation of a Schizophrenic Patient: Quality of Life, Level of Functioning, and Neuropsychological Symptomatology. Clinical Neuropsychologist, 1999, 13, 157-170.	1.4	6
103	Practical issues in medication compliance. Transplantation Proceedings, 1999, 31, 7S-9S.	0.5	20
104	How Long to Wait for a Response to Clozapine: A Comparison of Time Course of Response to Clozapine and Conventional Antipsychotic Medication in Refractory Schizophrenia. Schizophrenia Bulletin, 1999, 25, 709-719.	2.9	67
105	Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia. American Journal of Psychiatry, 1999, 156, 88-93.	5.1	75
106	Clozapine and Hospitalization. Psychiatric Services, 1999, 50, 114b-116.	1.3	0
107	Development and Cross-Cultural Translations of a 31-Item Quality of Life in Epilepsy Inventory. Epilepsia, 1998, 39, 81-88.	3.0	699
108	REPLY. Epilepsia, 1998, 39, 233-233.	3.0	9

#	Article	IF	Citations
109	Complex partial and secondarily generalized seizure patients: cognitive functioning prior to treatment with antiepileptic medication. Epilepsy Research, 1998, 30, 1-9.	1.3	66
110	Seizure measurement in clinical trials. Journal of Epilepsy, 1998, 11, 256-260.	0.6	9
111	Predictors of differential response to clozapine and haloperidol. Biological Psychiatry, 1998, 44, 475-482.	3.8	32
112	Does Participation in Psychosocial Treatment Augment the Benefit of Clozapine?. Archives of General Psychiatry, 1998, 55, 618.	12.7	68
113	Achieving Long-Term Continuance of Menopausal ERT/HRT. Menopause, 1998, 5, 69???76.	1.9	7
114	A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia. New England Journal of Medicine, 1997, 337, 809-815.	26.4	532
115	Title is missing!. , 1997, 19, 227-230.		10
116	Compliance With Contraceptives and Other Treatments. Obstetrics and Gynecology, 1996, 88, 4S-12S.	1.1	45
117	A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Research, 1996, 25, 113-118.	1.3	192
118	A Brief Questionnaire to Screen for Quality of Life in Epilepsy The QOLIE-10. Epilepsia, 1996, 37, 577-582.	3.0	362
119	Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures. Neurology, 1996, 47, 68-76.	0.7	114
120	Effect of Valproate on Cognitive Functioning. Archives of Neurology, 1996, 53, 1008.	6.8	91
121	Epilepsy-Reply. Archives of Neurology, 1996, 53, 476-477.	6.8	0
122	Development of the Quality of Life in Epilepsy Inventory. Epilepsia, 1995, 36, 1089-1104.	3.0	535
123	Dose Frequency and Dose Interval Compliance with Multiple Antiepileptic Medications During a Controlled Clinical Trial. Epilepsia, 1995, 36, 1111-1117.	3.0	125
124	Agreement between self reports and proxy reports of quality of life in epilepsy patients. Quality of Life Research, 1995, 4, 159-168.	1.7	135
125	Relationship between medication compliance and medical outcomes. American Journal of Health-System Pharmacy, 1995, 52, S27-S29.	0.6	50
126	The Relationship of Neuropsychological Functioning to Quality of Life in Epilepsy. Archives of Neurology, 1995, 52, 997-1003.	6.8	310

#	Article	IF	Citations
127	Quality of Life for People with Epilepsy. Neurologic Clinics, 1994, 12, 1-13.	2.0	82
128	Medication Compliance in Clinical Trials. Clinical Research and Regulatory Affairs, 1994, 11, 47-59.	0.3	0
129	Simultaneous HPLC Analysis of Carbamazepine and Carbamazepine Epoxide in Human Brain Microdialysate. Journal of Liquid Chromatography and Related Technologies, 1994, 17, 1567-1576.	1.2	12
130	A Pharmacodynamic Approach to the Estimate of Carbamazepine Autoinduction. Journal of Pharmaceutical Sciences, 1994, 83, 491-494.	2.4	21
131	Phenytoin concentrations in the human brain: An in vivo microdialysis study. Epilepsy Research, 1994, 18, 227-232.	1.3	64
132	Measurement of carbamazepine and carbamazepine epoxide in the human brain using in vivo microdialysis. Neurology, 1994, 44, 1469-1469.	0.7	44
133	A Clinimetric Approach to Assessing Quality of Life in Epilepsy. Epilepsia, 1993, 34, .	3.0	69
134	A Comparison of Valproate with Carbamazepine for the Treatment of Complex Partial Seizures and Secondarily Generalized Tonic–Clonic Seizures in Adults. New England Journal of Medicine, 1992, 327, 765-771.	26.4	707
135	Reproductive Function in Epilepsy. Epilepsia, 1991, 32, .	3.0	46
136	Medication Compliance in Epilepsy. Archives of Internal Medicine, 1991, 151, 1236.	8.1	10
137	Comparison of a Noninstrumented Immunoassay for Carbamazepine to High Performance Liquid Chromatography and Fluorescence Polarization Immunoassay. Epilepsia, 1990, 31, 480-484.	3.0	5
138	Compliance Declines Between Clinic Visits. Archives of Internal Medicine, 1990, 150, 1509.	8.1	317
139	Barbiturate-Related Connective Tissue Disorders. Archives of Internal Medicine, 1989, 149, 911.	8.1	29
140	How Often Is Medication Taken as Prescribed?. JAMA - Journal of the American Medical Association, 1989, 261, 3273.	14.4	748
141	Improvement in cognitive functioning and mood state after conversion to valproate monotherapy. Neurology, 1989, 39, 1640.	0.7	25
142	Can categorization of patient background problems be used to determine early termination in a clinical trial?. Contemporary Clinical Trials, 1988, 9, 47-63.	2.8	24
143	Antiepleptic drug medication monitoring. Contemporary Clinical Trials, 1988, 9, 257.	2.8	0
144	Variable Free and Total Valproic Acid Concentrations in Sole- and Multi-Drug Therapy. Therapeutic Drug Monitoring, 1986, 8, 411-415.	1.2	76

#	Article	IF	Citations
145	Epilepsy, Sex Hormones, and Antiepileptic Drugs. Epilepsia, 1985, 26, .	3.0	144
146	Comparison of Carbamazepine, Phenobarbital, Phenytoin, and Primidone in Partial and Secondarily Generalized Tonic–Clonic Seizures. New England Journal of Medicine, 1985, 313, 145-151.	26.4	1,143
147	What happens to study dropouts?. Contemporary Clinical Trials, 1984, 5, 307.	2.8	0
148	Human Serum Teratogenicity Studied by Rat Embryo Culture: Epilepsy, Anticonvulsant Drugs, and Nutrition. Epilepsia, 1984, 25, 205-216.	3.0	68
149	Treatment of seizures with medroxyprogesterone acetate. Neurology, 1984, 34, 1255-1255.	0.7	196
150	A design for the prospective evaluation of the efficacy and toxicity of antiepileptic drugs in adults. Neurology, 1983, 33, 14-25.	0.7	34
151	Historical perspective on the choice of antiepileptic drugs for the treatment of seizures in adults. Neurology, 1983, 33, 2-7.	0.7	72
152	A method of quantification for the evaluation of antiepileptic drug therapy. Neurology, 1983, 33, 26-37.	0.7	133
153	Principles in designing clinical trials for antiepileptic drugs. Neurology, 1983, 33, 8-13.	0.7	10
154	Which patients will be lost to follow-up?. Contemporary Clinical Trials, 1981, 2, 78.	2.8	2
155	Central case validation. Contemporary Clinical Trials, 1980, 1, 169.	2.8	1
156	Valproic Acid. Therapeutic Drug Monitoring, 1979, 1, 105-116.	1.2	85